Matt Campbell MD, MS Profile
Matt Campbell MD, MS

@DocMattCampbell

Followers
719
Following
2K
Media
86
Statuses
520

I am a genitorurinary medical oncologist at UT MD Anderson. I specialize in kidney, urothelial, adrenal and testicular cancer. all opinions are mine.

Houston, TX
Joined January 2024
Don't wanna be here? Send us removal request.
@DocMattCampbell
Matt Campbell MD, MS
26 days
An honor to take part in the DAVA GU Summit in Bermuda. Great start to the meeting. Proud of @CYJiangMD who presented her work on targeting TGF-B signaling in MTAP loss bladder cancer under mentorship of JJ Gao and @OAlhalabiMD sponsored by @ConquerCancerFd
2
11
27
@TiansterZhang
Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)
1 month
Dena Battle @RCCadvocate @kcCURE with poignant discussion of perceptions of cure in #kidneycancer. There’s a social contract and hope loaded in this word CURE β€” should we consider remission or other verbiage? @KidneyCancer #IKCSNA25
0
12
27
@TiansterZhang
Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)
1 month
The #kidneycancer godfather #NizarTannir receives the inaugural mentorship excellence award @KidneyCancer #IKCSNA25 - sharing the award w his mentees and reminding us to pass it forward, give the spotlight, #unstoppabletogether
0
11
33
@DocMattCampbell
Matt Campbell MD, MS
1 month
So happy to take part in #IKCSNA25, great Think Tank chaired by @PavlosMsaouel and @MVossMD focused on optimizing studies for patients with rare subtypes. Very proud today for our work on RCC bone mets modeling to be shown by @dr4gut1n from his work in the BoneMetLab @ED_PhD_
0
10
30
@CParkMD
π‚π‘πšπ§ππ₯𝐞𝐫 𝐏𝐚𝐫𝐀 πŒπƒ 𝐅𝐀𝐂𝐏
2 months
πŸ’‘Just released Practice changing study in NEJMπŸ‘‰ Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer. PFS DV vs chemo (median, 13.1 vs. 6.5 months; Overall survival DV vs Chemo (31.5 vs. 16.9 months;) objective response was DV 76.1% (95% CI, 70.3
0
46
95
@OncHahn
Andy Hahn
2 months
An insightful story about AVPC by @aaparicioMD: how to interpret the molecular alterations and how we’ve been treating them @MDAndersonNews #ESMO25
0
15
39
@DocMattCampbell
Matt Campbell MD, MS
2 months
Presidential EVP from KN905 in MIBC at #ESMO25 with incredibly strong data. PathCR of 57%! EFS and OS positive, a game changing study. ??? continuation of treatment with EV in those with pCR? Is cisplatin candidacy still relevant for MIBC? Ideal bladder sparing approach next?
1
12
32
@PavlosMsaouel
Pavlos Msaouel
2 months
Congratulations to @OncHahn, @JadChahoud and the entire team on completing this randomized investigator-initiated multicenter trial. Many thought it was impossible for such a comparison to be completed but you turned it into reality. @neerajaiims @PGrivasMDPhD @montypal
@OncHahn
Andy Hahn
2 months
Excited to see LenCabo published concomitant in @Annals_Oncology Plan to post a full tweetorial summarizing our results later @PavlosMsaouel
0
3
22
@CYJiangMD
Cindy Y. Jiang
2 months
Our poster assessing prognostic scores in 1L EVP pts. Belmont score: liver mets, ECOG >0, and Hgb<10 was best for predicting OS/PFS . Thanks to UNITE @koshkin85 for this opportunity and incredible mentorship by @DocMattCampbell and @OAlhalabiMD
1
10
25
@OncHahn
Andy Hahn
2 months
Excited to see LenCabo published concomitant in @Annals_Oncology Plan to post a full tweetorial summarizing our results later @PavlosMsaouel
@Annals_Oncology
Annals of Oncology
2 months
πŸ“’ #ESMO25 concomitant paper: results from the LenCabo phase II trial of lenvatinib + everolimus vs cabozantinib post PD-1 ICI in #mccRCC @OncHahn https://t.co/4EmwlwVhqE
1
20
57
@DocMattCampbell
Matt Campbell MD, MS
2 months
Very proud of @CYJiangMD for her great poster at #ESMO25 with prognostic scores for EVP treated patients from UNITE. Bellmunt criteria was the best to differentiate PFS/OS. Good for strata on front line mUC studies comparing to EVP. Great teamwork across centers. @OAlhalabiMD
1
8
35
@DocMattCampbell
Matt Campbell MD, MS
2 months
Congrats to Prof Camilo Jimenez @MDAndersonNews for presenting Ph2 belzutifan in advanced pheo/para with DCR of 80% median PFS nearly 2 years now published in @NEJM first targeted therapy FDA approved in this rare cancer type #ESMO25
0
2
7
@DocMattCampbell
Matt Campbell MD, MS
2 months
Congrats @OncHahn for the great presentation of the LenCabo study #ESMO25 now published in Annals of Oncology. Len/EV with significantly higher PFS than cabozantinib in IO experienced patients with mccRCC
2
17
44
@PavlosMsaouel
Pavlos Msaouel
6 months
First trial of PD1/VEGF bispecific in #kidneycancer just activated today and is @NazliDizman’s trial design project during her @MDAndersonNews heme/onc fellowship πŸ€“ πŸ‘‰ https://t.co/F2ryVQ8zyV @brian_rini @montypal @OncHahn @OAlhalabiMD @DocMattCampbell @ChadTangMD @SGoswamiMDPhD
@Uromigos
Uromigos
9 months
In our latest podcast, John Heymach from @MDAndersonNews reviews exciting PD1/VEGF bispecific data from the lung cancer. We review the data and discuss applications to GU malignancies. https://t.co/c0w1Svk3Ja
2
12
60
@PavlosMsaouel
Pavlos Msaouel
6 months
Tremendously enjoyed working with @Shounak_Gupta et al on this contemporary update of #RenalMedullaryCarcinoma pathology, pathophysiology, differential diagnosis & management. #kidneycancer #rarecancers #endRMC
@Shounak_Gupta
Sounak Gupta
6 months
Here is an update on medullary RCC. Thank you @PavlosMsaouel for your tremendous contribution to this article and thanks to @MichelleDunno17 for the invitation Open access at: https://t.co/lZ63zBeHNB
0
10
45
@glovedoc
Mike Glover
6 months
Surreal to be completing training in oncology, 14 years after beginning the journey as a freshman in college diagnosed with testicular cancer. I owe so much to my doctors, Dr. Ahmed and Dr. Einhorn, who showed me what it meant to treat patients (and people) with compassion
7
8
139
@PavlosMsaouel
Pavlos Msaouel
6 months
πŸ‘‡Latest treatment & research updates on #RenalMedullaryCarcinoma. #endRMC #RareCancers #kidneycancer
@kidneycan
KidneyCAN
6 months
RMC is one of the most aggressive and rare forms of #KidneyCancer. In our latest video, @PavlosMsaouel shares updates on how specialized treatments are improving outcomes for RMC patients. Explore the full Rare Subtypes playlist here: https://t.co/oEjQkQpdQ6 #AcceleratingCures
0
9
43
@mjmoussa_
Mohammad Jad Moussa, MD, MSc
6 months
White Coat Ceremony for my upcoming Internal Medicine Residency at Baylor College of Medicine @BCM_InternalMed - so grateful and blessed! πŸ™
6
6
98
@Sid423
Sid Sadler
6 months
We have a couple of years before she gets to making her own videos advocating for #RCC 🧑. Thanks for all you do @KidneyCancer πŸ‘πŸ»πŸ‘πŸ»
@KidneyCancer
Kidney Cancer
6 months
Thanks Parker for being the tiniest, mightiest advocate! @Sid423
1
1
12